Literature DB >> 16775330

High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice.

Caroline I Sellin1, Nathalie Davoust, Vanessa Guillaume, Dominique Baas, Marie-Françoise Belin, Robin Buckland, T Fabian Wild, Branka Horvat.   

Abstract

Measles virus (MV) infection causes an acute childhood disease, associated in certain cases with infection of the central nervous system and development of a severe neurological disease. We have generated transgenic mice ubiquitously expressing the human protein SLAM (signaling lymphocytic activation molecule), or CD150, recently identified as an MV receptor. In contrast to all other MV receptor transgenic models described so far, in these mice infection with wild-type MV strains is highly pathogenic. Intranasal infection of SLAM transgenic suckling mice leads to MV spread to different organs and the development of an acute neurological syndrome, characterized by lethargy, seizures, ataxia, weight loss, and death within 3 weeks. In addition, in this model, vaccine and wild-type MV strains can be distinguished by virulence. Furthermore, intracranial MV infection of adult transgenic mice generates a subclinical infection associated with a high titer of MV-specific antibodies in the serum. Finally, to analyze new antimeasles therapeutic approaches, we created a recombinant soluble form of SLAM and demonstrated its important antiviral activity both in vitro and in vivo. Taken together, our results show the high susceptibility of SLAM transgenic mice to MV-induced neurological disease and open new perspectives for the analysis of the implication of SLAM in the neuropathogenicity of other morbilliviruses, which also use this molecule as a receptor. Moreover, this transgenic model, in allowing a simple readout of the efficacy of an antiviral treatment, provides unique experimental means to test novel anti-MV preventive and therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775330      PMCID: PMC1488937          DOI: 10.1128/JVI.00209-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Wild-type measles virus infection in human CD46/CD150-transgenic mice: CD11c-positive dendritic cells establish systemic viral infection.

Authors:  Masashi Shingai; Naokazu Inoue; Tsuyoshi Okuno; Masaru Okabe; Takashi Akazawa; Yasuhide Miyamoto; Minoru Ayata; Kenya Honda; Mitsue Kurita-Taniguchi; Misako Matsumoto; Hisashi Ogura; Tadatsugu Taniguchi; Tsukasa Seya
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

2.  Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling.

Authors:  Bumsuk Hahm; Matthew J Trifilo; Elina I Zuniga; Michael B A Oldstone
Journal:  Immunity       Date:  2005-02       Impact factor: 31.745

3.  Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo.

Authors:  D Christiansen; P Devaux; B Réveil; A Evlashev; B Horvat; J Lamy; C Rabourdin-Combe; J H Cohen; D Gerlier
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Productive measles virus brain infection and apoptosis in CD46 transgenic mice.

Authors:  A Evlashev; E Moyse; H Valentin; O Azocar; M C Trescol-Biémont; J C Marie; C Rabourdin-Combe; B Horvat
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Measles virus infection in a transgenic model: virus-induced immunosuppression and central nervous system disease.

Authors:  M B Oldstone; H Lewicki; D Thomas; A Tishon; S Dales; J Patterson; M Manchester; D Homann; D Naniche; A Holz
Journal:  Cell       Date:  1999-09-03       Impact factor: 41.582

6.  SLAM (CDw150) is a cellular receptor for measles virus.

Authors:  H Tatsuo; N Ono; K Tanaka; Y Yanagi
Journal:  Nature       Date:  2000-08-24       Impact factor: 49.962

7.  The H gene of rodent brain-adapted measles virus confers neurovirulence to the Edmonston vaccine strain.

Authors:  W P Duprex; I Duffy; S McQuaid; L Hamill; S L Cosby; M A Billeter; J Schneider-Schaulies; V ter Meulen; B K Rima
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  Design of a small-molecule entry inhibitor with activity against primary measles virus strains.

Authors:  Richard K Plemper; Joshua Doyle; Aiming Sun; Andrew Prussia; Li-Ting Cheng; Paul A Rota; Dennis C Liotta; James P Snyder; Richard W Compans
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

9.  Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.

Authors:  Philippe Desprès; Chantal Combredet; Marie-Pascale Frenkiel; Clarisse Lorin; Michel Brahic; Frédéric Tangy
Journal:  J Infect Dis       Date:  2004-12-10       Impact factor: 5.226

10.  Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice.

Authors:  G Grant Welstead; Caterina Iorio; Ryan Draker; Jane Bayani; Jeremy Squire; Sompong Vongpunsawad; Roberto Cattaneo; Christopher D Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

View more
  19 in total

1.  Measles virus-induced immunosuppression in SLAM knock-in mice.

Authors:  Ritsuko Koga; Shinji Ohno; Satoshi Ikegame; Yusuke Yanagi
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

2.  Sequence analysis of morbillivirus CD150 receptor-Signaling Lymphocyte Activation Molecule (SLAM) of different animal species.

Authors:  J Sarkar; V Balamurugan; A Sen; P Saravanan; B Sahay; K K Rajak; T J Rasool; V Bhanuprakash; R K Singh
Journal:  Virus Genes       Date:  2009-08-09       Impact factor: 2.332

3.  Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides.

Authors:  C Mathieu; D Huey; E Jurgens; J C Welsch; I DeVito; A Talekar; B Horvat; S Niewiesk; A Moscona; M Porotto
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

4.  Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infection.

Authors:  Shinji Ohno; Nobuyuki Ono; Fumio Seki; Makoto Takeda; Shinobu Kura; Teruhisa Tsuzuki; Yusuke Yanagi
Journal:  J Virol       Date:  2006-11-29       Impact factor: 5.103

5.  Type I Interferon Receptor Signaling Drives Selective Permissiveness of Astrocytes and Microglia to Measles Virus during Brain Infection.

Authors:  Jeremy Charles Welsch; Benjamin Charvet; Sebastien Dussurgey; Omran Allatif; Noemie Aurine; Branka Horvat; Denis Gerlier; Cyrille Mathieu
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

6.  Expression of the Sendai (murine parainfluenza) virus C protein alleviates restriction of measles virus growth in mouse cells.

Authors:  Masaharu Iwasaki; Yusuke Yanagi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-06       Impact factor: 11.205

7.  Measles Virus Bearing Measles Inclusion Body Encephalitis-Derived Fusion Protein Is Pathogenic after Infection via the Respiratory Route.

Authors:  Cyrille Mathieu; Marion Ferren; Eric Jurgens; Claire Dumont; Ksenia Rybkina; Olivia Harder; Debora Stelitano; Silvia Madeddu; Giuseppina Sanna; Dayna Schwartz; Sudipta Biswas; Diana Hardie; Takao Hashiguchi; Anne Moscona; Branka Horvat; Stefan Niewiesk; Matteo Porotto
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

Review 8.  Making it to the synapse: measles virus spread in and among neurons.

Authors:  V A Young; G F Rall
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

9.  Fatal measles virus infection prevented by brain-penetrant fusion inhibitors.

Authors:  Jeremy C Welsch; Aparna Talekar; Cyrille Mathieu; Antonello Pessi; Anne Moscona; Branka Horvat; Matteo Porotto
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

10.  Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150).

Authors:  Claudia S Antunes Ferreira; Marie Frenzke; Vincent H J Leonard; G Grant Welstead; Christopher D Richardson; Roberto Cattaneo
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.